Table 3.

Clinical Treatment Score post-5 years (CTS5): estimation of disease recurrence 5 to 10 years after diagnosis of hormone receptor-positive breast cancer patients treated with 5 years of endocrine treatment

Risk groups	5- to 10-year disease recurrence risk (%)	95% CI (%)	No. of events
ATAC dataset (N = 4735)
Low	2.5	1.8–3.4	40
Intermediate	7.7	6.3–9.5	95
High	20.3	17.2–24	195
BIG 1–98 dataset (N = 6711)
Low	3.6	2.7–4.9	64
Intermediate	6.9	5.6–8.5	108
High	17.3	14.8–20.1	198